Physician profile
Miyako Igari
NPI 1225398787
$696.99
in general payments reported to CMS, 2019-2025
11 companies · $18.79 in 2025
The $18.79 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $72.09 · 2021: $410 · 2022: $108 · 2023: $71.38 · 2024: $16.50 · 2025: $18.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $253.70 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $186.18 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.22 | 2021-2023 | Eliquis |
| Amgen INC. | $40.62 | 2020-2025 | Repatha |
| Boston Scientific Corporation | $38.41 | 2023 | Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.56 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $22.50 | 2021 | |
| Atricure, INC. | $19.09 | 2021 | |
| Astellas Pharma US INC | $18.22 | 2021 | |
| Kestra Medical Technology Services, INC. | $16.50 | 2024 | Assure Wcd |
| Novo Nordisk INC | $13.99 | 2023 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miyako Igari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.